About the Company and its Mission:

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO). As a development stage biotech company ProMIS’ mission is to discover and develop best in class precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

The Company’s scientific foundation is centered on the growing consensus that prion forms of misfolded proteins are key drivers of neurodegenerative diseases. Prion forms of misfolded proteins are characterized by their neurotoxicity and ability to progressively spread throughout the brain, killing neurons. Numerous neurodegenerative diseases exhibit toxic, prion-like protein misfolding, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Recent published evidence indicates that for a given misfolded protein there exist several prion-like strains, representing targets against which specific therapeutics can be developed.

Core Science & Technology. The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center. For over two decades, Neil Cashman has been among the leaders in the field of misfolded proteins (with over 300 publications and over 10,000 citations and 45 patent applications), and is one of several leading researchers of strain specific protein misfolding in neurodegenerative diseases.

Discovery Platform & Intellectual Property. ProMIS Neurosciences utilizes two proprietary computational discovery technologies, ProMIS™ and Collective Coordinates, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS Neurosciences has a robust patent estate relating to misfolded SOD1 in ALS and multiple patents for disease specific epitopes (targets) and monoclonal antibodies (mAbs) selectively targeting toxic misfolded Amyloid beta oligomers (AβO) in AD.